Related Experiment Videos
[Adjuvant endocrine therapy for breast cancer]
12nd Dept. of Surgery, Gunma University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1995
Summary
Tamoxifen improves survival in breast cancer patients, especially those over 50. Antiestrogens like tamoxifen are more effective in postmenopausal women due to estrogen level changes.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Context:
- Tamoxifen (TAM) significantly improves survival in breast cancer patients, as per EBCTCG.
- Adjuvant TAM therapy is more effective in patients over 50 and with treatment durations exceeding two years.
Purpose:
- To investigate the efficacy of antiestrogens in different menopausal groups.
- To explore novel adjuvant endocrine therapies for breast cancer.
Summary:
- Long-term tamoxifen use can increase estrogen levels in premenopausal patients, potentially blocking its antitumor effect.
- Animal models showed similar effects with toremifene and TAT-59, suggesting antiestrogens are more effective in postmenopausal women.
- Luteinizing hormone-releasing hormone (LH-RH) agonists and aromatase inhibitors show promise as adjuvant therapies.
Impact:
- Combination therapies involving TAM, LH-RH agonists, or aromatase inhibitors may offer new effective adjuvant endocrine treatments.
- Future clinical applications may include combinations of endocrine therapy with biological response modifiers or vitamin D3.